Table 1 Characteristics of all included HIV-1 patients and patients carrying a wild-type virus or a virus with transmitted drug resistance mutations to NRTI, NNRTI, or PI drug class
Characteristics | Categories | Total | Wild-type | NRTI TDRMa | NNRTI TDRMa | PI TDRMa |
|---|---|---|---|---|---|---|
Patients | 4317 | 3933 | 218 | 125 | 107 | |
Continent of origin, no (%) | Western Europe | 2404 (56) | 2164 (55) | 135 (62) | 85 (68) | 66 (62) |
Eastern Europe & Central Asia | 919 (21) | 848 (22) | 48 (22) | 16 (13) | 17 (16) | |
Sub-Saharan Africa | 472 (11) | 442 (11) | 12 (6) | 11 (9) | 12 (11) | |
Other | 354 (8) | 325 (8) | 16 (7) | 9 (7) | 8 (7) | |
Unknown | 168 (4) | 154 (4) | 7 (3) | 28 (2) | 4 (4) | |
Gender, no. (%) | Male | 3411 (79) | 3084 (78) | 190 (87) | 107 (86) | 88 (82) |
Risk group, no. (%) | MSM | 2084 (48) | 1852 (47) | 138 (63) | 79 (63) | 57 (53) |
Hetero | 1501 (35) | 1402 (36) | 50 (23) | 28 (22) | 37 (35) | |
Injecting drug use | 355 (8) | 337 (9) | 7 (3) | 10 (8) | 5 (5) | |
Unknown | 377 (9) | 342 (9) | 23 (11) | 8 (6) | 8 (7) | |
Subtype, no. (%) | B | 2855 (66) | 2553 (65) | 183 (84) | 94 (75) | 78 (73) |
non-B | 1381 (32) | 1306 (33) | 31 (14) | 27 (22) | 27 (25) | |
Unknown | 81 (2) | 74 (2) | 4 (2) | 4 (3) | 2 (2) | |
Duration of infection, no (%) | <1 year | 1236 (29) | 1099 (28) | 75 (34) | 49 (39) | 41 (38) |
1-2 years | 144 (3) | 130 (3) | 8 (4) | 6 (5) | 2 (2) | |
Unknown | 2937 (68) | 2704 (69) | 135 (62) | 70 (56) | 64 (60) | |
Plasma HIV-RNA, median (IQR), log copies/ml | 4.9 (4.3-5.3) | 4.9 (4.3-5.3) | 4.9 (4.3-5.5) | 4.8 (4.1-5.5) | 4.7 (4.3-5.2) | |
CD4 cell count, median (IQR), cells/mm3 | 352 (180–540) | 350 (177–534) | 400 (186–572) | 426 (275–577) | 386 (251–593) | |
Age, median years (IQR) | 35 (29–42) | 35 (29–42) | 35 (28–42) | 35 (29–43) | 34 (29–39) | |